News
US biotech company raises seed round to advance therapies for endocrine disorders
HBMAT’s programmes aim to deliver precision therapies for endocrine disorders
The US biotech company HBM Alpha Therapeutics (HBMAT) has completed seed financing to advance its novel antibody therapies to treat common endocrine disorders such as congenital adrenal hyperplasia and polycystic ovary syndrome.
The company was founded on the work of Harbour BioMed‘s antibody discovery and development capabilities, and expertise in the molecular pathogenesis and treatment of endocrine disorders of founder, Dr Joseph Majzoub.
HBMAT’s programmes aim to deliver precision therapies for endocrine disorders, targeting a pathway for CAH and PCOS.
CAH is a rare-autosomal recessive genetic disease with a defective CYP21A2 gene. Patients diagnosed with the condition have life-threatening deficiencies of glucocorticoid and mineralocorticoid, with limited treatment options and no new therapeutic modalities in over 50 years.
While the current standard of care is associated with inevitable treatment-related side effects, specifically cushing syndrome, caused by having too much of a hormone called cortisol in the body and hyperandrogenism.
HBMAT is developing HAT001 which focuses on treating hyperandrogenism without causing cushing syndrome.
According to the company’s website, HAT001 would effectively cause reversible pharmacologic adrenalectomy, converting CAH patient treatment into that for primary adrenal insufficiency, which can be treated with much lower, physiological doses of glucocorticoid.
As a common and chronic endocrine disorder, PCOS affects over 10 per cent women of reproductive age around the world and is the most common cause of anovulatory female infertility.
HBMAT is also developing HAT002 for PCOS, targeting a pathway shared with CAH. The financing will be used to advance the programmes into the clinical stage.
“I am very excited about this unique opportunity of developing antibody therapeutics for CAH, a rare genetic disease and PCOS impacting women’s health,” said Jingsong Wang, founder, chairman and CEO of Harbour BioMed.
“The company is thrilled to take these exciting programmes to the next level and translate this therapeutic antibody with very impressive biological functions into clinical benefits for patients with significant unmet medical needs.”
Dr Philip Reilly, a clinical geneticist and biotech entrepreneur, and board member of HBMAT, added: “I’ve worked closely with patient groups and tried to help those suffering from rare diseases over the past decades.
“HBMAT has already identified a clinical development candidate with excellent characteristics in preclinical functional activities including in vivo efficacy in various relevant animal models.
“I look forward to moving the development candidate into clinical trials and beyond.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Fertility
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Wellness2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Entrepreneur4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






